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A B S T R A C T
Nitric oxide plays a prominent role in the cardiovascular system and much attention has been devoted in the last
years on deciphering the regulation of human endothelial nitric oxide synthase (eNOS) expression. Epigenetic-
based mechanisms have a key role in the eNOS expression and their pathologic perturbations may have profound
eﬀects on the steady state RNA levels in the endothelium. The human eNOS promoter lacks a canonical TATA
box and it does not contain a proximal CpG island. A diﬀerentially DNA methylated region (DMR) in the native
eNOS proximal promoter is involved in gene expression regulation. Here we describe a quantitative, sensitive
and cost-eﬀective method that, relying on a novel normalization strategy, allows the quantiﬁcation of DNA
methylation status of the positive regulatory domains (PRDI, PRDII) and cAMP response element (CRE) in
human eNOS promoter. This technique will enable to explore the functional relevance of DNA methylation
perturbations of eNOS promoter both under pathological and physiological conditions.
1. Introduction
Three isoforms of nitric oxide synthase (NOS) encoded by 3 separate
genes on diﬀerent chromosomes catalyze the production of nitric oxide
(NO) in mammals, namely neuronal NOS (NOS1), inducible NOS (iNOS
or NOS2), and endothelial NOS (eNOS or NOS3). These NOS isoforms
are characterized by diﬀerent regulation and cell-speciﬁc distribution.
eNOS is constitutively expressed in the vascular endothelium and re-
sponsible for the majority of NO produced [1–3]. NO, as signaling
molecule with antithrombotic and antiatherogenic properties, plays a
fundamental role in cardiovascular physiology. NO deﬁciency is known
to induce systemic and pulmonary hypertension, abnormal vascular
remodeling, defective angiogenesis, pathological healing in response to
vascular injury, and impaired mobilization of stem and progenitor cells
[4]. Given the prominent role of NO in the cardiovascular system, much
attention has been focused on deciphering the regulation of eNOS. To
this regard important transcriptional, post-transcriptional, and post-
translational mechanisms have been described [5]. Recently, particular
emphasis has been placed on epigenetics, as it provides a new ob-
servation point for understanding eNOS transcriptional control para-
digms in vascular endothelial cells, both in health and disease states
[6–8]. The human eNOS promoter lacks a canonical TATA box and it
does not contain a proximal CpG island, but a diﬀerentially methylated
region (DMR) whose DNA methylation status plays an important role in
the regulation of the transcription, as well as in the endothelial cell-
speciﬁc expression of the gene [9]. DNA methylation has been im-
plicated in various cellular processes including transcriptional regula-
tion. Methyl-CpG is recognized as a gene silencing signal and their
speciﬁc presence at promoter level prevents the interaction of the
transcription factors with their binding sites [10–12]. Indeed, whereas
non-endothelial cells, such as vascular smooth cells and CD34+ stem
cells, are highly methylated at proximal promoter sequences, en-
dothelial cells lack DNA methylation in this same region [6]. The DMR
encompasses cis-DNA elements known to be necessary for eNOS tran-
scription, such as the positive regulatory domains I and II (PRDI, PRDII)
whose methylation, along with cAMP Response Element (CRE), im-
pedes and regulates eNOS gene transcription [4,13]. Given the im-
portant role of DNA methylation in eNOS transcriptional regulation,
here we describe a quantitative, sensitive and cost-eﬀective two-step
qPCR method to evaluate PRDI, PRDII and CRE methylation status of
eNOS promoter. The method, relies on innovative normalization
strategy settled by our laboratory for other genes [14,15] that allows
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the detection and quantiﬁcation of small methylation-density diﬀer-
ences between pre-ampliﬁed DNA samples. This technique will enable
to explore the functional relevance of DNA methylation perturbations
of eNOS promoter both under pathological and physiological condi-
tions.
2. Materials and methods
2.1. Cell culture
Primary human cord blood CD34+ cells and human umbilical vein
endothelial cells (HUVECs) were obtained from American Type Culture
Collection (ATCC). CD34+ stem cells were maintained in StemSpan
(StemCell Technologies) containing 50 ng/mL stem cell factor (SCF,
Peprotech), 50 ng/mL FMS-Like Tyrosine Kinase 3 (FLT-3, Peprotech),
20 ng/mL for each ligand interleukin (i.e. IL-6, IL-3, Peprotech).
HUVECs were maintained in EGM2 medium (Lonza) supplemented
with 2mM L-glutamine, 10% heat-inactivated fetal bovine serum (FBS,
Gibco) and 1% penicillin/streptomycin. All cultured cells were in-
cubated at 37 °C with 5% CO2.
2.2. DNA extraction, whole-genome ampliﬁcation and fully methylated
genomic DNA preparation
Genomic DNA (gDNA) from CD34+ stem cells and HUVECs was
isolated by PureLink Genomic DNA kit (Invitrogen) following manu-
facturer's protocols. Nucleic acid samples were quantiﬁed by NanoDrop
ND-1000 Spectrophotometer (Thermo Fisher Scientiﬁc) and its in-
tegrity was analyzed by 1% agarose gel electrophoresis. Whole–genome
ampliﬁcation (WGA) was performed by use of REPLI-g Mini Kit
(Qiagen) according to manufacturer's protocol starting from 10 ng of
gDNA extracted from primary HUVECs. The WGA product was puriﬁed
by QIAquick PCR Puriﬁcation Kit (Qiagen) and quantiﬁed with
NanoDrop ND-1000 Spectrophotometer. The WGA product was used as
fully un-methylated DNA [16]. Fully methylated gDNA (Sss1-DNA) was
prepared by treating gDNA from HUVECs with CpG Methyltransferase
(M.SssI, New England Biolabs) according to manufacturer's instruc-
tions.
2.3. Sodium bisulﬁte genomic modiﬁcation
Bisulﬁte conversion and subsequent puriﬁcation was performed by
MethylCode Bisulﬁte Conversion Kit (Invitrogen) following manufac-
turer's protocols, starting from 300 ng of gDNA. After conversion, DNA
was eluted in 10 μL (30ng/μL).
2.4. Primers and PCR conditions for two-step PCR
The eNOS gene sequence was obtained from ENSEBL (http://www.
ensembl.org) and carefully analyzed to identify the PRDI, PRDII and
CRE regions at proximal promoter level, as described by Chan and
coworkers [6]. Seven primers for eNOS promoter were designed
(Fig. 1): two external methylation independent primers (MIP1Fw,
MIP1Rv), one nested forward methylation independent primer
(MIP2Fw) for data normalization, and four nested methylation speciﬁc
primers for the CpGs in CRE (MSP1Fw, MSP1Rv), PRDI and PRDII
(MSP2Fw, MSP2Rv) regions. The sequences of both MIP1 primer set
and nested MIP2Fw were designed to ﬂank PRDI, PRDII and CRE re-
gions and not to bind CpG dinucleotides. Nested MIP2Fw primer was
speciﬁcally used only in the second PCR step along with the reverse
MIP1Rv primer for data normalization. Nested MSP primers contained
at least two CpG sites to render the primers as speciﬁc as possible to the
methylated template. Primer list is reported in Table 1.
Our two-step method is based on two sequential PCR reactions. The
ﬁrst PCR (MIP1-PCR) is performed with conventional Thermal Cycler
(BioRad) in 25 μl reaction mixture composed of 30 ng (if not diﬀerently
stated) of bisulﬁte-converted DNA, 0.5 μM for each primer (MIP1Fw,
MIP1Rv), 1x PCR Buﬀer, 200 μM dNTP mix, and 0.5 μL HotStarTaq
DNA Polymerase (Qiagen). PCR conditions are 95 °C for 15min for
initial heat activation, followed by 40 cycles of 95 °C for 30s, 57 °C for
45s, 72 °C for 1min and a ﬁnal extension cycle of 72 °C for 20min. The
ampliﬁcation product (879 bp, referred to as input PCR product),
puriﬁed with the QIAquick PCR Puriﬁcation Kit (Qiagen), is then
quantiﬁed by NanoDrop ND-1000 Spectrophotometer and stored at
−20 °C for the subsequent step.
The second-step consists of three separate nested qPCR reactions in
which the input product of the MIP1-PCR (879 bp) is used as template.
Two reactions are performed with nested MSP primer sets (MSP1-qPCR
using MSP1Fw/MSP1Rv and MSP2-qPCR using MSP2Fw/MSP2Rv), and
one with nested MIP primer set (MIP2-qPCR using MIP2Fw/MIP1Rv).
Speciﬁcally, 1 μl of puriﬁed and diluted input of the MIP1-PCR product
was added to 10 μl of qPCR reaction mixture composed of 0.5 μM
primer pair and 5 μL SYBR Green Supermix 2X (BioRad). All reactions
were performed in separate wells of 96-well reaction plate on CFX96
Real–Time System PCR (Bio-Rad) and the samples analyzed in technical
duplicate or triplicate. The qPCR conditions were as follows: 95 °C for
3min followed by 40 cycles of 95 °C for 15s, 60 °C for 50s with 1 cycle
of dissociation step to generate a melting curve. For data analysis
samples with Ct above 35 were considered as beyond detection
threshold and discarded. The input DNA normalization for the qPCRs
was performed with the ΔCt method. The Ct of MIP2-qPCR was sub-
tracted to the Ct of MSP1-qPCR and MSP2-qPCR (ΔCt). The formula
2−ΔCt was used to calculate the relative amount of methylated DNA in
the region investigated by MSP-qPCRs.
2.5. Bisulﬁte Sanger sequencing
For bisulﬁte sequencing analysis, the endpoint PCR product from
ﬁrst ampliﬁcation step of CD34+ stem cells and HUVECs were resolved
by 1% agarose gel electrophoresis. The bands of the expected size (879
bp) were excised and puriﬁed with QIAquick Gel Extraction Kit
(Qiagen), cloned into pCR4-TOPO-TA cloning vector (Invitrogen) and
transformed in E. Coli strain DH5α. Ten colonies were randomly picked
and directly used for PCR ampliﬁcation to verify the vector insertion by
T3 and T7 primers. Three positive colonies from each sample were
Sanger sequenced with T3 primer with the help of an external service
(GATC Biotech, Constance, AG). The analysis of sequences was per-
formed with BioEdit software and methylation density assessed and
represented by QUMA software (http://quma.cdb.riken.jp/).
2.6. RNA extraction, cDNA preparation and eNOS gene expression analysis
by qPCR
Total RNA from primary human cord blood CD34+ stem cells and
HUVECs was isolated by use of Direct-zol RNA Kit (Zymo Research)
following manufacturer's protocols and quantiﬁed by NanoDrop ND-
1000 Spectrophotometer. Five hundred ng of total RNA was converted
to cDNA with the Superscript III kit (Life Technologies) according to the
manufacturer's protocol. The qPCR reactions were performed on CFX96
Real–Time System PCR. The reaction mixtures consisted of 15 μL con-
taining 7.5 μL SYBR Green Supermix, 7.5 ng cDNA and 0.5 μM of each
primer. The cycling protocol started with 95 °C for 3min followed by 40
cycles of 95 °C for 15s, 60 °C for 45s and slow denaturation to generate a
melting curve. Relative gene expression was calculated with the ΔCt
method. The Ct values of the gene were subtracted (ΔCt) to that of the
housekeeping genes (β2-microglobulin). Primer list is reported in
Table 1.
2.7. Western Blot
CD34+ stem cells and HUVECs were lysed by RIPA buﬀer (150mM
NaCl, 50 mM Tris-HCl, 1% NP-40, 0.5% sodium deoxycholate, and
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Fig. 1. eNOS gene.
(A) Schematic representation from −889 to −10 bp of human eNOS promoter containing PRDI, PRDII and CRE elements (in the frame). Red and green arrows
indicate the annealing position of MIP and MSP primer sets respectively within the analysed region. DNA sequence before (B) and after bisulﬁte treatment (C) of the
region of interest. In yellow are highlighted CpG dinucleotide resolution involved in eNOS transcription regulation.
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0.1% SDS) supplemented with a protease inhibitor cocktail (Sigma
Aldrich), quantiﬁed by Pierce BCA Protein Assay (Thermo Scientiﬁc),
and then subjected to Western Blot analyses as previously described
[17]. The membrane was incubated with a primary antibody speciﬁc
for eNOS (Sc-654, C-20; Santa Cruz Biotechnology) and then with a
peroxidase-conjugated anti-Rabbit IgG secondary antibody (GE
Healthcare). Beta-actin expression level was evaluated with a perox-
idase-conjugated primary antibody (A3854, AC-15; Sigma Aldrich) and
used to normalize eNOS signal. The membrane was developed using
enhanced chemiluminescence detection system (Thermo Scientiﬁc),
acquired with ChemiDoc Imaging System (BioRad), and quantiﬁed with
Image Lab 6.0.1 (BioRad).
2.8. Statistical analysis
Results were expressed as mean ± SEM. All experiments were
performed at least in triplicate, unless stated otherwise. Unpaired two-
tailed Students’ T-test was performed and a value of P≤ 0.05 was
considered signiﬁcant. Statistical analyses were performed and graphs
designed utilizing the statistical software GraphPad Prism 5.00
(GraphPad Software).
3. Results
3.1. Principle of the technique
The human eNOS gene has been mapped to the chromosome 7q35-
36 [9] and consists of 26 exons spanning 21 kb of gDNA. Two clustered
cis-regulatory regions have been identiﬁed in the proximal TATA-less
eNOS promoter: PRDI (−104/-95 upstream transcription start site
(TSS)) and PRDII (−210/-117) that along with CRE region (−740/-
731) are known to regulate eNOS transcription [6] (Fig. 1A, B and C).
The method schematized in Fig. 2 consists of one conventional PCR
followed by three qPCRs. In the conventional PCR (MIP1-PCR) the
methylation independent primers (MIP1Fw, MIP1Rv) are ﬁrst used to
speciﬁcally amplify a portion of eNOS promoter (from−889 to−10 bp
relative to TSS) encompassing the three regions of interest [6]. This
MIP1-PCR ampliﬁes an 879 bp long fragment regardless its methylation
status (Fig. 2). In the second step the diluted 879 bp endpoint product
from the MIP1-PCR (referred to as input PCR product) is subjected to
three separate SYBR Green-based qPCRs. In particular, two reactions
quantify the methylation status of CRE (398 bp) and PRDI/PRDII (126
bp) regions with the use of nested methylation-speciﬁc primers
MSP1Fw, MSP1Rv (MSP1-qPCR) and MSP2Fw, MSP2Rv (MSP2-qPCR;
Fig. 2, green arrows); while the third reaction (MIP2-qPCR) amplify a
251 bp region by nested methylation independent MIP2Fw and MIP1Rv
primers (Fig. 2, red arrows). The cycle thresholds (Ct) deriving from
this latter qPCR is used to normalize the Ct from the MSP primer sets
and to calculate the relative quantiﬁcation of methylation status in the
samples (2−ΔCt). After the end of qPCR program a dissociation step is
immediately performed for melting curve analysis.
3.2. Sensitivity and accuracy of two-step PCR method
Serial dilutions (0.1 ng/μL to 0.1 fg/μL) of fully methylated DNA,
obtained from the pre-ampliﬁcation of in vitro methylated gDNA (Sss1-
DNA) converted with bisulﬁte, were used to evaluate the ampliﬁcation
eﬃciency (AE, %) and detection limit of MSP1, MSP2 and MIP2 primer
sets. Both MSP2 and MIP2 primer sets showed 100% of AE, whereas
MSP1 primer set was slightly below (80%, Fig. S1). In line with AE
analysis, the detection limit of MSP1 primer sets was 0.1 fg while the
same amount was still eﬃciently ampliﬁed by MSP2 and MIP2 primer
sets, even if the melting proﬁle of MIP2 end-products revealed an initial
primer dimer formation, also conﬁrmed by gel electrophoresis (Fig. S2).
To evaluate the ability of primer sets to discriminate between me-
thylated and un-methylated DNA, as well as the quantiﬁcation limit and
accuracy of the method, in vitro Sss1-methylated and WGA un-methy-
lated DNA were bisulﬁte converted and pre-ampliﬁed by MIP1 primer
sets. PCR products were then mixed to obtain solutions with the same
total DNA concentration, but composed by increasing percentage of
methylated DNA. Brieﬂy, input MIP1-PCR products from both Sss1-
DNA- and WGA-DNA-PCR were serially diluted to 0.5 ng/μL up to
0.01 pg/μL. Afterwards, the methylated and un-methylated DNA dilu-
tions were properly mixed to obtain solutions containing equal con-
centration of total DNA (0.5 ng/μL to 0.01 pg/μL) and increasing
amount of methylated DNA (0% 20%, 40%, 60%, 80% and 100%). The
solutions were then analyzed by two-step PCR method and the data,
plotted against their respective methylation percentage, were subjected
to linear regression analysis. The analysis revealed a strong linear re-
lationship across the normalized data points and percentage of me-
thylated templates in all used solutions (Fig. 3A and B and Figs. S3A and
B). In particular, the lowest total DNA concentration (0.01 pg/μL) still
showed a robust ampliﬁcation signal for both methylated and reference
amplicons (Fig. S3A, B and C), demonstrating the ability of this method
to detect and reliably quantify as low as 0.002 pg of methylated DNA in
0.01 pg of total DNA template (corresponding to the 20% of methylated
DNA in the linear regression analysis). Moreover, the high reproduci-
bility of reference Ct in curves made with DNA solutions ranging from
0.01 pg/μL to 0.5 ng/μL and constituted by increasing amount of me-
thylated DNA, demonstrated that the nested primers used for normal-
ization (MIP2Fw and MIP1Rv) maintained the same ampliﬁcation ef-
ﬁciency throughout reactions, also in the presence of template with
diﬀerent methylation state (Fig. 3C and Fig. S3C), an essential pre-
requisite for accurate quantiﬁcations.
To further demonstrate the method sensitivity, we directly per-
formed qPCR assays on bisulﬁte-converted gDNA and compared the
results with those obtained with two-step PCR. Ten pg of bisulﬁte-
converted Sss1-methylated gDNA and 10 pg of puriﬁed input PCR
product, resulting from ampliﬁcation of bisulﬁte-converted Sss1-me-
thylated DNA, were used as template in MSP1-qPCR, MSP2-qPCR and
MIP2-qPCR. The analysis of the qPCR ampliﬁcation plots showed that
only the Ct value of the reactions performed directly on bisulﬁte-treated
gDNA (one-step PCR) was beyond detection threshold (Ct= 35) in
MSP1-qPCR, MSP2-qPCR and 20 cycles higher in MIP2-qPCR when
compared with two-step PCR (Fig. 4A). In addition, the analysis of
melting curve proﬁles of endpoint PCR products showed unspeciﬁc
ampliﬁcation products or primer dimer formation when bisulﬁte-
treated gDNA samples were directly used in the assay but not with the
two-step method (Fig. 4B, C and D). The melting curve data were fur-
ther conﬁrmed by gel electrophoretic analysis of PCR endpoint products
(inserts in Fig. 4B, C and D). Taken together these data show that the
inclusion of a ﬁrst ampliﬁcation step in the assay enables the analysis of
bisulﬁte-treated gDNA quantities that, when directly analyzed by the
one-step PCR approach, result in no product formation or in very late
Table 1
Bisulﬁte treated
DNA
Name Sequence 5' —˃ 3′
MIP1 Fw AGTGTTTGGAGAGTGTTGGTGTAT
MIP1 Rv ACAAAACCCTAACCTTTTCCTTAAA
MIP2 Fw TAGGGTTTTGTTGGATATTTGGGT
MSP1 Fw TTCGGGAAGCGTGCGTTA
MSP1 Rv ACGAAAAAACCTTCGACCTCAC
MSP2 Fw CGGAATTTAGGCGTTCGGTTT
MSP2 Rv TACTAACCCTCGCCCCGC
cDNA
eNOS Fw GTGGCTGGTACATGAGCACT
eNOS Rv TGGCTAGCTGGTAACTGTGC
β2-Microglobulin
Fw
GGACTGGTCTTTCTATCTCTTGTAC
β2-Microglobulin
Rv
ACCTCCATGATGCTGCTTAC
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threshold cycles, thus allowing DNA methylation proﬁling from small
amounts of gDNA starting material. Moreover, the two-step PCR ap-
proach eliminates both primer dimer formation and the possibility of
false priming on non-speciﬁc templates, overcoming a frequent problem
observed in direct gDNA ampliﬁcation [18,19]. Therefore, as already
demonstrated with a nested PCR approach [20], this method showed
higher sensitivity and speciﬁcity in target template detection than one-
step PCR. All in all, this technique allows a relative quantiﬁcation of
DNA methylation and, once positive and negative controls are assessed,
the samples under investigation can be analyzed and compared.
3.3. Method validation and melting proﬁle analysis of qPCR products
To validate the quantiﬁcation eﬃciency of the method in biological
samples we analyzed two cell types characterized by low/null and high
eNOS expression: CD34+ stem cells and HUVECs [6,21]. Bisulﬁte
treated gDNA isolated from the cells was used to investigate the me-
thylation status of CRE and PRDI/PRDII regions of eNOS promoter
(Fig. 5A). As expected all analyzed regions displayed high methylation
levels in CD34+ stem cells and null/low in HUVECs (Fig. 5B and C).
The results were further conﬁrmed at nucleotide resolution level by
bisulﬁte Sanger sequencing, the “gold standard”method in methylation
studies. After sequencing the number of methylated sites and percen-
tage of methylation were assessed. As shown in Fig. 6A data deriving
from bisulﬁte Sanger sequencing were consistent with those obtained
by the two-step PCR method, thus conﬁrming its validity. Consistently,
eNOS mRNA and protein expression in HUVECs and CD34+ stem cells
(Fig. 6B and C) correlated with the methylation level of CRE and PRDI/
PRDII regions.
The melt proﬁle of qPCR endpoint products was also analyzed
(Fig. 6D, E and F). While MSP1-qPCR and MSP2-qPCR end products
deriving from both HUVECs and CD34+ stem cells displayed similar
melting temperature, MIP2-qPCR products diﬀered considerably. Spe-
ciﬁcally, the melt temperature of CD34+ stem cell amplicons was two
grades higher than that of HUVECs (78 °C vs 76 °C, respectively;
Fig. 6F). Bisulﬁte-converted DNA templates harboring various degrees
of methylation at their CpG sites generate amplicons with distinct
melting temperatures. Generally, the higher is the GC-content the
higher is the melting temperature. In line, amplicons of fully methy-
lated CD34+ stem cell templates were characterized by a right-shifted
melting proﬁle, whereas HUVECs showed a left-shifted melting in-
dicating that all CpG sites were not methylated. Therefore, the analysis
and interpretation of melting curves can also serve as useful and ef-
fective strategy to assess the methylation density of CpG sites on target
template. All qPCR end products were also resolved on 1% agarose gel
to conﬁrm the presence of only one band of the expected size (inserts in
Fig. 6D, E and F).
4. Discussion
Chan and coworkers demonstrated that DNA methylation is im-
portant in controlling transcription of eNOS gene [6]. This epigenetic
modiﬁcation is extensively studied and numerous techniques have been
developed for its investigation [22,23]. The most common PCR-based
DNA methylation techniques comprise methylation speciﬁc PCR (MSP),
MethyLight and methylation-sensitive high resolution melting (MS-
HRM) and bisulﬁte sequencing PCR (BSP and cloning-based BSP). All
these techniques include, as ﬁrst step, the conversion of the DNA with
Fig. 2. Method overview.
Schematic diagram of technique based on two step
PCR. Bisulﬁte-converted gDNA is used as template
in the ﬁrst ampliﬁcation of 879 bp region encom-
passing PRDI, PRDII and CRE elements (MIP1Fw
and MIP1Rv). Nested qPCR consists of three in-
dependent reactions performed with diluted input
PCR product from the ﬁrst PCR round. Two nested
methylation speciﬁc primer reactions (MSP1-qPCR
and MSP2-qPCR, in green arrows) evaluate the
methylation status of target template. The third
methylation independent reaction (MIP2-qPCR, in
red arrows) is used as reference control to normalize
the amount of methylated target detected by the
MSP-qPCRs with the ΔCt method. Black circles (•)
are a schematic representation of methylated CpG.
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bisulﬁte [24] and have as intrinsic characteristic the inability to dis-
criminate 5mC and 5hmC [25]. MSP, although simple and highly
sensitive technique [26], is not a quantitative method and can lead to
an overestimation of methylation state especially when looking for very
low methylation diﬀerences. MSP has been upgraded to quantitative
assay by the use of ﬂuorescent TaqMan probe designed for the me-
thylated region of interest and a reference gene for normalization
(MethyLight technique) [27]. In this case any signal from non-speciﬁc
ampliﬁcation is eliminated. However, the design of the assay can be
complicated by the introduction of the probe. Moreover, the use of
primers and probes speciﬁc for completely methylated templates may
lead to failure of the assay or to biased quantitative results when
heterogeneous methylation patterns with large variations between
consecutive CpGs complementary to the probe are present [27]. The
normalization data of MethyLight technique relies on reference genes
ampliﬁed from bisulﬁte converted-DNA that is more prone to PCR bias
and biased results because of its low sequence diversity.
While BSP techniques holds several technical challenges such as
poor signal quality and low sensitivity [28], cloning-based BSP is more
accurate, but requires at least six sequencing reactions to obtain
meaningful results, and the data obtained are referred to as DNA–-
methylation haplotypes [29,30]. Although considered the “gold stan-
dard method” in methylation studies, cloning-based BSP is an expensive
and time-consuming technique that requires a large number of samples
Fig. 3. Quantitative accuracy of the two-step PCR method.
Linear regression analysis between normalized quantiﬁcation and percentage of methylated template for MSP1-qPCR (A) and MSP2-qPCR primer sets (B) for 0.5, 0.1,
0.01 ng/μL of total input DNA. For each data point three independent reactions were performed. The correlation coeﬃcient (R2) are indicated on the plotted graph.
(C) Reproducibility of reference Ct in curves made with increasing amount of input PCR product (0.01 ng/μL to 0.5 ng/μL) constituted by increasing amount of
methylated DNA. For every input of total DNA each dot represents a diﬀerent percentage of methylated DNA (0%, 20%, 40%, 60%, 80% and 100%).
Fig. 4. Sensitivity of the two-step PCR method.
(A) MSP1-qPCR, MSP2-qPCR and MIP2-qPCR per-
formed on input PCR product (two-step PCR) had
signiﬁcantly higher sensitivity than qPCR per-
formed directly on bisulﬁte-converted gDNA (one-
step PCR). Ct values from 10 pg of input PCR pro-
ducts obtained from bisulﬁte-converted gDNA ap-
peared earlier than in the direct ampliﬁcation of
10 pg of bisulﬁte-converted gDNA. (B, C and D)
Melting curve proﬁles of endpoint PCR products
generated from bisulﬁte-converted gDNA and two-
step qPCR. The inserts represent gel electrophoretic
analysis of PCR endpoint products to conﬁrm the
absence of nonspeciﬁc amplicons formation.
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and sequences in order to obtain signiﬁcant results especially when
very small methylation diﬀerences need to be detected. Our two-step
PCR method set up to investigate the methylation status of CRE and
PRDI/PRDII regions of eNOS promoter combines quantitative and
melting curve proﬁling analysis. Both designed MSP primer sets re-
cognize the 70% of 5mC involved in the regulation of eNOS gene
transcription indicating the screening eﬃciency of the technique. The
introduction of a ﬁrst ampliﬁcation step makes this method highly
sensitive, speciﬁc and accurate allowing the detection of as low as
500 pg of bisulﬁte-converted gDNA (roughly corresponding to the DNA
content of 100 cells). As previously demonstrated [14], the pre-ampli-
ﬁcation of a genomic fragment, which includes both the target sequence
Fig. 5. Method validation on biological samples.
(A) Schematic representation from−889 to−10 bp
of human eNOS promoter containing PRDI, PRDII
and CRE elements. Methylation status of PRDI,
PRDII and CRE elements in CD34+ stem cells and
HUVECs obtained by the two-step PCR method
using (B) MSP1-qPCR and (C) MSP2-qPCR primer
set (***p < 0.001 vs. CD34+ stem cells by unpaired
t-test).
Fig. 6. Method validation by bisulﬁte Sanger sequencing.
(A) Sanger sequencing of the region of interest (879 bp) ampliﬁed by MIP1 primer set. Three randomly selected sequences representative of CpG methylation in PRDI,
PRDII and CRE elements in HUVECs and CD34+ stem cells are reported. Open dots are un-methylated cytosine, whereas methylated cytosine are indicated with black
dots. On the right, methylation percentage of eNOS promoter in HUVECs and CD34+ stem cells, respectively obtained after QUMA software analysis, are indicated.
(B) Analysis of eNOS mRNA expression in CD34+ stem cells and HUVECs by qPCR. Data are reported as 2−ΔCt (***p < 0.001 vs. CD34+ stem cells by unpaired t-
test). (C) eNOS protein expression level in CD34+ stem cells and HUVECs by Western Blot. Representative melting curve proﬁles of (D)MSP1-qPCR, (E)MSP2-qPCR
and (F)MIP2-qPCR products from un-methylated (HUVECs) and fully methylated (CD34+ stem cells) template. In the inserts, agarose gel electrophoresis analysis of
each PCR endpoint products to conﬁrm the presence of only one band of the expected size.
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and the reference control, allows a robust quantiﬁcation of the me-
thylation and reduces qPCR normalization bias [30]. The expression of
eNOS is very tightly regulated by epigenetic mechanisms whose per-
turbations in disease may have profound eﬀects on eNOS steady state
RNA levels in the endothelium. Indeed, decreases in eNOS mRNA ex-
pression in cardiovascular have been well documented [31–35].
Nevertheless, the epigenetic mechanisms sustaining eNOS expression
deﬁcit are not well understood. Here we provide a simple, sensitive and
reliable experimental tool useful to study eNOS DNA methylation in a
variety of physiological and pathophysiological contexts that require a
real-time PCR instrument only.
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